Grabar Law Office is investigating claims on behalf of shareholders of LifeMD, Inc. (NASDAQ: LFMD). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

LifeMD describes itself as a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management and hormone therapy.

As alleged in a recently filed federal securities fraud class action complaint, LifeMD, Inc. (NASDAQ: LFMD), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, Defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT YOU CAN DO NOW: If you purchased LifeMD, Inc. (NASDAQ: LFMD) shares prior to May 7, 2025, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased LifeMD shares between May 7, 2025 and August 5, 2025, you can participate in the class action.